Sara Pérez Jaume
Ayudante de investigación
Research group
Professional network profiles
Last Publications
- Mora J, Climent A, Roldan-Molina M, Flores MC, Varo A, Pérez-Jaume S, Jou-Munoz C, Celma MS, Lazaro JJ, Cheung I, Castañeda-Heredia A, Gorostegui M, Rodriguez E, Chamorro S, Muñoz JP and Cheung NK Desensitizing the autonomic nervous system to mitigate anti-GD2 monoclonal antibody side effects Frontiers in oncology . 14: 1380917-1380917.
- Gorostegui M, Muñoz JP, Pérez-Jaume S, Simao-Rafael M, Cristina Larrosa Espinosa, Garraus-Oneca M, Salvador-Marcos N, Lavarino C, Krauel L, Mañe S, Castañeda-Heredia A and Mora J Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy Cancers . 16(9): .
- Fresno Cañada C, Gispets Parcerisas J, Del Prado-Sanchez C, Puigventós E, Pérez-Jaume S, Salvador-Hernandez H, Llorca Cardeñosa A and Prat-Bartomeu J DRI Triton SS-OCT applied to detect choroidal nodules in paediatric patients affected by NF1. Heliyon . 10(8): .
Projects
- Project name:
- SGR 2022-2024_Grup de recerca en tumors del desenvolupament
- Leader
- Jaume Mora Graupera
- Funding entities:
- Agaur - Agència de Gestió d'Ajuts Universitaris i de Recerca
- Code
- 2021 SGR 01612
- Starting - finishing date:
- 2022 - 2025
- Project name:
- Nuevas técnicas para la caracterización molecular completa y la mejora del seguimiento de la enfermedad mínima residual en leucemia aguda pediátrica
- Leader
- Mireia Camós Guijosa, Nerea Vega García
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI21/00213
- Starting - finishing date:
- 2022 - 2025
- Project name:
- Desarrollo de clasificadores epigenéticos para el Cáncer Pediátrico (ECPC)
- Leader
- Cinzia Emilia Lavarino
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI20/00519
- Starting - finishing date:
- 2021 - 2025
News
-
Researchers at IRSJD develop a method to predict the efficacy of a potent nanomedicine in a severe childhood cancer
Researchers at IRSJD have developed a method that predicts the anticancer efficacy of nab-paclitaxel, a well-known nanomedicine, in mouse models, for treatment of Ewing sarcoma, a severe cancer affecting the bones and soft tissue of children and adolescents.
-
Survival rate of high-risk neuroblastoma patients treated with next-generation immunotherapy at SJD Barcelona Children's Hospital
Researchers of SJD Barcelona Children's Hospital and of Institut de Recerca Sant Joan de Déu (IRSJD) have published the results of treatment with the humanised anti-GD2 antibody Naxitamab (DanyelzaR) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF; LeukineR) in high-risk neuroblastoma patients.
More activities
-
Defensa tesi doctoral: Sara Pérez Jaume
Auditorio J Plaza del Hospital Sant Joan de Déu y online